Alpioner Therapeutics (2023)
法国生物技术公司Alpioner Therapeutics正在开发一款针对铜绿假单胞菌（Pseudomonas aeruginosa）的创新疫苗。该疫苗基于一种名为“代谢活性灭活细菌”（MMA）的技术平台，其核心在于使用经过处理、已失去致病能力但仍保持代谢活性的灭活细菌。
该疫苗通过双重机制发挥作用：一方面，它能正向调控SST3的表达，从而激发针对多种抗原的广泛体液免疫应答；另一方面，它可强烈刺激白细胞介素-17（IL-17）的分泌，有效激活Th17型免疫反应。这种Th17反应对于实现肺部铜绿假单胞菌的完全清除至关重要。
这一研发方向旨在应对铜绿假单胞菌感染，尤其是对囊性纤维化等慢性肺部疾病患者构成的严重威胁。目前该疫苗仍处于临床前开发阶段。
Alpioner Therapeutics Advances Novel Anti-Pseudomonas Vaccine Platform
Alpioner Therapeutics is developing a vaccine targeting *Pseudomonas aeruginosa* (Pa), a major cause of hospital-acquired infections, particularly in immunocompromised patients and those with cystic fibrosis. The company's approach centers on a unique platform using a metabolically active but dead bacterium (MMA).
The core innovation lies in the MMA's dual mechanism of action. First, it positively controls the expression of SST3, which drives a broad humoral immune response against multiple bacterial antigens. Second, it strongly activates the secretion of interleukin-17 (IL-17), stimulating a robust Th17-type immune response. This combined action is designed to achieve complete clearance of *Pseudomonas aeruginosa* from the lungs, addressing a critical unmet need in treating persistent and antibiotic-resistant infections.
Alpioner Therapeutics développe un vaccin anti-pseudomonas reposant sur le développement d’une bactérie morte mais métaboliquement active (MMA) qui à la fois contrôle positivement l’expression du SST3 pour une réponse humorale variée contre différents antigènes, et active fortement la sécrétion d’Il-17 stimulant la réponse de type Th17 nécessaire à la clairance complète de Pa des poumons.
Alpioner Therapeutics is developing a novel Pseudomonas vaccine using a metabolically active but dead bacterial platform to enhance immune clearance, addressing a major antibiotic-resistant infection.
Alpioner Therapeutics — Biotech developing advanced bacterial vaccines, based in France.
Monitor — Early-stage platform with a novel mechanism targeting a high-need infection, but clinical validation is pending.